Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Capital Expenditures of $39000.0 for Q1 2026, up 105.22% on a QoQ basis from -$747000.0 in Q2 2025, and up 129.41% year-over-year from $17000.0 in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Capital Expenditures history runs 7 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- Quarterly Capital Expenditures rose 129.41% year-over-year to $39000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$708000.0 (down 2623.08% YoY) and the FY2025 annual result came in at -$730000.0, down 2254.84% from the prior year.
- Capital Expenditures was $39000.0 for Q1 2026 at Aurinia Pharmaceuticals, up from -$747000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $507000.0 in Q2 2023 and bottomed at -$747000.0 in Q2 2025.
- A 5-year average of -$22866.7 and a median of $17000.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures soared 1200.0% — and 2025, when it sank 683.59%.
- Aurinia Pharmaceuticals' Capital Expenditures stood at $205000.0 in 2022, then sank by 296.59% to -$403000.0 in 2023, then surged by 89.33% to -$43000.0 in 2024, then slumped by 1637.21% to -$747000.0 in 2025, then jumped by 105.22% to $39000.0 in 2026.
- Business Quant data shows AUPH's Capital Expenditures at $39000.0 in Q1 2026, -$747000.0 in Q2 2025, and $17000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | 39,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39,000.00 |
| Mar 31, 2026 | 39,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Sep 30, 2024 | -128,000.00 |
| Sep 30, 2024 | -128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | -403,000.00 |
| Dec 31, 2023 | -403,000.00 |
| Sep 30, 2023 | -105,000.00 |
| Sep 30, 2023 | -105,000.00 |
| Jun 30, 2023 | 507,000.00 |
| Jun 30, 2023 | 507,000.00 |